Nature Communications (Sep 2020)
CLR01 protects dopaminergic neurons in vitro and in mouse models of Parkinson’s disease
- Nora Bengoa-Vergniory,
- Emilie Faggiani,
- Paula Ramos-Gonzalez,
- Ecem Kirkiz,
- Natalie Connor-Robson,
- Liam V. Brown,
- Ibrar Siddique,
- Zizheng Li,
- Siv Vingill,
- Milena Cioroch,
- Fabio Cavaliere,
- Sarah Threlfell,
- Bradley Roberts,
- Thomas Schrader,
- Frank-Gerrit Klärner,
- Stephanie Cragg,
- Benjamin Dehay,
- Gal Bitan,
- Carlos Matute,
- Erwan Bezard,
- Richard Wade-Martins
Affiliations
- Nora Bengoa-Vergniory
- Oxford Parkinson’s Disease Center (OPDC) and Department of Physiology, Anatomy and Genetics, Oxford University
- Emilie Faggiani
- Institut des Maladies Neurodégénératives, UMR 5293, Univ. de Bordeaux
- Paula Ramos-Gonzalez
- Departamento de Neurociencias, Achucarro Basque Center for Neuroscience, and Centro de Investigación Biomédica en Red en Enfermedades Neurodegenerativas (CIBERNED), Universidad del País Vasco (UPV/EHU)
- Ecem Kirkiz
- Oxford Parkinson’s Disease Center (OPDC) and Department of Physiology, Anatomy and Genetics, Oxford University
- Natalie Connor-Robson
- Oxford Parkinson’s Disease Center (OPDC) and Department of Physiology, Anatomy and Genetics, Oxford University
- Liam V. Brown
- Mathematical Institute, Oxford University
- Ibrar Siddique
- Department of Neurology, Brain Research Institute and Molecular Biology Institute, University of California, Los Angeles
- Zizheng Li
- Department of Neurology, Brain Research Institute and Molecular Biology Institute, University of California, Los Angeles
- Siv Vingill
- Oxford Parkinson’s Disease Center (OPDC) and Department of Physiology, Anatomy and Genetics, Oxford University
- Milena Cioroch
- Oxford Parkinson’s Disease Center (OPDC) and Department of Physiology, Anatomy and Genetics, Oxford University
- Fabio Cavaliere
- Departamento de Neurociencias, Achucarro Basque Center for Neuroscience, and Centro de Investigación Biomédica en Red en Enfermedades Neurodegenerativas (CIBERNED), Universidad del País Vasco (UPV/EHU)
- Sarah Threlfell
- Oxford Parkinson’s Disease Center (OPDC) and Department of Physiology, Anatomy and Genetics, Oxford University
- Bradley Roberts
- Oxford Parkinson’s Disease Center (OPDC) and Department of Physiology, Anatomy and Genetics, Oxford University
- Thomas Schrader
- Institute of Organic Chemistry, University of Duisburg-Essen
- Frank-Gerrit Klärner
- Institute of Organic Chemistry, University of Duisburg-Essen
- Stephanie Cragg
- Oxford Parkinson’s Disease Center (OPDC) and Department of Physiology, Anatomy and Genetics, Oxford University
- Benjamin Dehay
- Institut des Maladies Neurodégénératives, UMR 5293, Univ. de Bordeaux
- Gal Bitan
- Department of Neurology, Brain Research Institute and Molecular Biology Institute, University of California, Los Angeles
- Carlos Matute
- Departamento de Neurociencias, Achucarro Basque Center for Neuroscience, and Centro de Investigación Biomédica en Red en Enfermedades Neurodegenerativas (CIBERNED), Universidad del País Vasco (UPV/EHU)
- Erwan Bezard
- Institut des Maladies Neurodégénératives, UMR 5293, Univ. de Bordeaux
- Richard Wade-Martins
- Oxford Parkinson’s Disease Center (OPDC) and Department of Physiology, Anatomy and Genetics, Oxford University
- DOI
- https://doi.org/10.1038/s41467-020-18689-x
- Journal volume & issue
-
Vol. 11,
no. 1
pp. 1 – 14
Abstract
CLR01 is a molecular tweezer that inhibits protein aggregation. Here the authors show that CLR01 protects dopaminergic neurons in vitro and in vivo in human neurons and in mouse models showing potential as a disease-modifying therapy for Parkinson’s disease.
